These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31074791)

  • 1. Sacubitril/Valsartan Augments Postprandial Plasma Concentrations of Active GLP-1 When Combined With Sitagliptin in Men.
    Wewer Albrechtsen NJ; Mark PD; Terzic D; Hansen LH; Andersen UØ; Hartmann B; Carr RD; Gustafsson F; Deacon CF; Holst JJ; Goetze JP; Plomgaard P
    J Clin Endocrinol Metab; 2019 Sep; 104(9):3868-3876. PubMed ID: 31074791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes.
    Wewer Albrechtsen NJ; Møller A; Martinussen C; Gluud LL; Rashu EB; Richter MM; Plomgaard P; Goetze JP; Kjeldsen S; Hansen LH; Gustafsson F; Deacon CF; Holst JJ; Madsbad S; Bojsen-Møller KN
    Diabetes Obes Metab; 2022 Oct; 24(10):2017-2026. PubMed ID: 35676803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Concentrations of C-Type Natriuretic Peptides Increase with Sacubitril/Valsartan Treatment in Healthy Young Men.
    Thonsgaard S; Prickett TCR; Hansen LH; Wewer Albrechtsen NJ; Andersen UØ; Terzic D; Plomgaard P; Gustafsson F; Goetze JP; Mark PD
    Clin Chem; 2022 May; 68(5):713-720. PubMed ID: 35175317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
    Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
    Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma.
    Andersen UØ; Terzic D; Wewer Albrechtsen NJ; Dall Mark P; Plomgaard P; Rehfeld JF; Gustafsson F; Goetze JP
    Endocr Connect; 2020 May; 9(5):438-444. PubMed ID: 32348960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
    Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
    Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neprilysin inhibition improves intravenous but not oral glucose-mediated insulin secretion via GLP-1R signaling in mice with
    Esser N; Mongovin SM; Parilla J; Barrow BM; Mundinger TO; Fountaine BS; Larmore MJ; Castillo JJ; Akter R; Hull RL; Zraika S
    Am J Physiol Endocrinol Metab; 2022 Mar; 322(3):E307-E318. PubMed ID: 35128957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.
    Deacon CF; Wamberg S; Bie P; Hughes TE; Holst JJ
    J Endocrinol; 2002 Feb; 172(2):355-62. PubMed ID: 11834453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
    Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
    Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery.
    Svane MS; Bojsen-Møller KN; Nielsen S; Jørgensen NB; Dirksen C; Bendtsen F; Kristiansen VB; Hartmann B; Holst JJ; Madsbad S
    Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E505-14. PubMed ID: 26786780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of GLP-1 receptor signalling by sacubitril/valsartan: Implications for patients with poor glycaemic control.
    Mahtani K; Patel B; Wang B; Barron A
    Int J Cardiol; 2022 Nov; 367():81-89. PubMed ID: 35944765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
    Kishimoto M; Noda M
    Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study.
    Stevens JE; Horowitz M; Deacon CF; Nauck M; Rayner CK; Jones KL
    Aliment Pharmacol Ther; 2012 Aug; 36(4):379-90. PubMed ID: 22738299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?
    Andersen ES; Lund A; Bagger JI; Andreasen C; Grøndahl MF; Deacon CF; Hartmann B; Holst JJ; Knop FK; Vilsbøll T
    Diabetes Obes Metab; 2018 Aug; 20(8):1937-1943. PubMed ID: 29654643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.